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Declining Intensive Care Unit Mortality of COVID-19: A  
Multi-Center Study
Sohaib Roomia, g, Syed Omar Shahb, Waqas Ullaha, Shan Ul Abedina, Karyn Butlerc, 
 Kelly Schiersd, Benjamin Kohle, Erika Yoof, Matthew Vibbertb, Jack Jallob
Abstract
Background: Coronavirus disease 2019 (COVID-19) mortality has 
waned significantly over time; however, factors contributing towards 
this reduction largely remain unidentified. The purpose of this study 
was to evaluate the trend in mortality at our large tertiary academic 
health system and factors contributing to this trend.
Methods: This is a retrospective cohort study of intensive care unit 
(ICU) patients diagnosed with COVID-19 between March and Au-
gust 2020 admitted across 14 hospitals in the Philadelphia area. Col-
lected data included demographics, comorbidities, admission risk of 
mortality score, laboratory values, medical interventions, survival 
outcomes, hospital and ICU length of stay (LOS) and discharge 
disposition. Chi-square (χ2) test, Fisher exact test, Cochran-Mantel-
Haenszel method, multinomial logistic regression models, independ-
ent sample t-test, Mann-Whitney U test and one-way analysis of vari-
ance (ANOVA) were used.
Results: A total of 1,204 patients were included. Overall mortality 
was 39%. Mortality declined significantly from 46% in March to 14% 
in August 2020 (P < 0.05). The most common underlying comorbidi-
ties were hypertension (60.2%), diabetes mellitus (44.7%), dyslipi-
demia (31.6%) and congestive heart failure (14.7%). Hydroxychlo-
roquine (HCQ) use was more commonly associated with the patients 
who died, while the use of remdesivir, tocilizumab, steroids and dura-
tion of these medications were not significantly different. Peak values 
of ferritin, lactate dehydrogenase (LDH), C-reactive protein (CRP) 
and D-dimer levels were significantly higher in patients who died (P < 
0.05). The mean hospital LOS was significantly longer in the patients 
who survived compared to the patients who died (18 vs. 12, P < 0.05).
Conclusions: The mortality of patients admitted to our ICU system 
significantly decreased over time. Factors that may have contribut-
ed to this may be the result of a better understanding of COVID-19 
pathophysiology and treatments. Further research is needed to eluci-
date the factors contributing to a reduction in the mortality rate for 
this patient population.
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Introduction
Coronavirus disease 2019 (COVID-19) caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) spread 
across the globe in a matter of months. On March 11, 2020, 
the World Health Organization (WHO) labeled it as a pan-
demic and issued emergency use authorization (EUA) for vari-
ous drugs to counter the devastation caused by this “once in a 
century pandemic” [1]. Various off-label and compassionate 
use drugs have been trialed based on in vitro activity against 
SARS-CoV-2. Efficacy has been limited except for low-dose 
dexamethasone and remdesivir as per preliminary data of the 
Recovery trial [2, 3]. By the end of August 2020, more than 30 
million cases have been reported worldwide, 6.5 million cases 
in the USA and a total death toll of around 200,000 in the USA.
Although the total number of cases is increasing over 
time, recent data from Europe suggest that the mortality rate 
from COVID-19 has declined in all age groups, and the older 
age groups drive the overall reduction. In Germany, the case 
fatality rate declined from 29% in mid-April to 11% by the end 
of July in patients aged 80 and above, while a sharper decline 
from 9% in March to 2% in July was observed in the age group 
between 60 and 79 years [4]. However, the intensive care unit 
(ICU) mortality rate varies significantly between countries and 
over time, which renders it to be highly uncertain. A recent 
study from Emory University reported an ICU mortality rate of 
30.9% at the end of April 2020, which was significantly lower 
compared to earlier mortality rates of 50-70% as per previous 
reports from China, Italy and Seattle [5].
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The primary outcome of this study was to evaluate the 
trend in COVID-19 mortality at our large academic health sys-
tem consisting of 14 hospitals serving the greater Philadelphia 
area and southern New Jersey. Secondary outcomes evaluated 
differences in demographics, comorbidities, ICU interventions 
and outcomes of the patients who survived compared to pa-
tients who died during the study period.
Materials and Methods
Study design and participants
This is a retrospective cohort study of all patients with con-
firmed COVID-19 infection who were admitted to the ICUs 
across 14 affiliated hospitals of the Jefferson Health System 
between March 1, 2020, and August 31, 2020. Jefferson Health 
is a multi-state non-profit health system with its main hospital 
located in Center City, Philadelphia. With its affiliate hospi-
tals, the system serves the population of the greater Philadel-
phia area and southern New Jersey. During the study period, 
all patients admitted to the ICU were cared for by a dedicated 
critical care team with standard ICU staffing ratios. There was 
no shortage of medications or critical care equipment during 
the study period. The Institutional Review Board approved this 
study and the Research Ethics Committee waived the require-
ment for informed consent.
Data collection
Data were extracted from electronic medical records (Epic, 
Verona WI and Sunrise, Chicago, IL) using a standardized 
data collection form by our data analytics team. Collected 
data included patient demographics (age, gender, ethnicity), 
comorbidities (diabetes mellitus, hypertension, dyslipidemia, 
heart failure, smoking, chronic obstructive pulmonary disease, 
asthma, atrial fibrillation, chronic kidney disease, and stroke), 
medications (hydroxychloroquine (HCQ), tocilizumab (TCZ), 
remdesivir, steroids), respiratory support (mechanical inter-
vention, bilevel positive airway pressure (BiPAP), high-flow 
nasal cannula (HFNC)), and adjunctive interventions (extra-
corporeal membrane oxygenation (ECMO), epoprostenol 
sodium, nitric oxide). Laboratory values (C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), D-dimer, ferri-
tin, fibrinogen, lactate dehydrogenase (LDH) were collected 
on admission, day 1, day 10 and peak values during the hos-
pital stay (highest lab values irrespective of the day of hospi-
talization). Admission risk of mortality score was determined 
using software developed by Vizient Inc. (Irving, Texas) and 
was classified as minor, moderate, major, and extreme. Patient 
outcomes and length of stay (LOS) were also collected. Real-
time polymerase chain reaction (RT-qPCR) was used to de-
tect the virus in nasopharyngeal, tracheal, or other respiratory 
specimens; and patients were considered to have confirmed 
infection if the initial or repeat test was positive. For patients 
with readmission during the study period, data from the first 
admission were used.
Statistical analysis
A Chi-square (χ2) test was used for comparison of categorical 
data and Fisher exact test was adopted if the expected count 
in more than 20% cells was less than 5. Continuous variables 
were presented as means and standard deviations, while cate-
gorical variables were reported in percentages and proportions. 
To quantify the association between the dichotomous categori-
cal variables, an unadjusted odds ratio (uOR) was obtained us-
ing a Cochran-Mantel-Haenszel method. Multinomial regres-
sion analysis was used to adjust our outcome for all variables 
collected. For normally and abnormally distributed continu-
ous data, an independent sample t-test and Mann-Whitney U 
test were used, respectively. A one-way analysis of variance 
(ANOVA) was used to compare differences in the mean of 
continuous variables for multiple in-hospital complications. A 
two-sided α < 0.05 was considered statistically significant with 
corroborating inference from a 95% confidence interval (CI). 
Statistical analyses were performed using the SPSS software 
(version 25, IBM Corp).
Results
Demographics and baseline characteristics
A total of 1,204 patients were admitted to the ICU with 
confirmed SARS-CoV-2 infection. There were 715 males 
(59.3%), and a majority of patients were white (51.6%). The 
mean age in years for the alive and dead was 62 and 70 years, 
respectively (P < 0.05). Besides age, there was no statistically 
significant difference between those who survived compared 
to the ones who died in terms of demographics and coexist-
ing comorbidities (Table 1). The most common underlying 
comorbidities were hypertension (60.2%), diabetes mellitus 
(44.7%), dyslipidemia (31.6%) and congestive heart failure 
(14.7%) in both the comparison groups. A significantly high-
er number of patients who died had a risk of mortality score 
categorized as extreme compared to the people who lived 
(96% vs. 70%, P < 0.05). ESR on admission was significantly 
higher among the patients who died (P < 0.05), while CRP, 
LDH, ferritin and fibrinogen were not significantly different 
between the two groups (P = 0.36, P = 0.09, P = 0.29, and 
P = 0.41, respectively). Comorbidities and the use of ster-
oids, HCQ, TCZ or remdesivir during hospitalization were 
not significantly different between those who survived and 
those who died.
Mortality
The overall mortality was 39%. Mortality declined significant-
ly over time from 46% in March to 14% in August 2020 with 
a statistically significant difference between the months. For 
head-to-head comparison between individual months, we used 
August as a reference, and mortality of each individual month 
was compared against it. The adjusted odds of mortality were 
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significantly lower in August as compared to March, April and 
May (P < 0.05, Table 2).
Intervention and outcomes
Compared to those who survived, patients who died in the ICU 
were more likely to require invasive mechanical ventilation 
(79% vs. 46%, P < 0.05), BiPAP (40% vs. 29%, P < 0.05) or 
epoprostenol sodium (15% vs. 3.4%, P < 0.05, Table 3). The 
use of inhaled pulmonary vasodilators was relatively uncom-
mon (0.16%) and 27 patients (2.24%) received ECMO. Use of 
HCQ was more commonly associated with the patients who 
died compared to the patients who survived (56% vs. 44%, P < 
0.05), while the use of remdesivir, TCZ, steroids and duration 
of these medications were not significantly different between 
Table 1.  Demographic Information, Baseline Comorbidities and Admission Laboratory Values
Parameters All (n) Alive n (%) Dead n (%) P value
N 1,204 734 (61) 470 (39) < 0.05
Age (mean) 66 62 70 < 0.05
  Sex
  Male 715 433 (59) 282 (60) 0.73
  Female 489 301 (41) 188 (40)
Race
  White 622 380 (52) 242 (52) 0.45
  African American 418 248 (34) 170 (36)
  Hispanic 32 24 (3) 8 (2)
  Asian 99 63 (9) 36 (8)
  Unknown 32 18 (3) 14 (3)
BMI (mean) 32 32 32 0.87
HTN 725 434 (59) 291 (62) 0.34
Dyslipidemia 381 235 (32) 146 (31) 0.73
Diabetes 539 320 (44) 219 (47) 0.31
COPD 26 13 (2) 13 (3) 0.25
CKD 129 72 (10) 57 (12) 0.21
CHF 177 117 (16) 60 (13) 0.13
Smoking 192 126 (17) 66 (14) 0.15
Asthma 122 83 (11) 39 (8) 0.09
Atrial fibrillation 128 79 (11) 49 (10) 0.85
Admission mortality risk score
  Minor 3 3 (0.4) 0 (0) < 0.05
  Moderate 30 30 (4) 0 (0)
  Major 169 154 (21) 15 (3)
  Extreme 964 515 (70) 449 (95)
  Not available 38 32 (4) 6 (1)
Mean labs value on day 1
  CRP, mg/L 13.2 12.7 13.8 0.36
  D-dimer, ng/mL 2,101 1,902 2,296 0.40
  ESR, mm/h 5912 4483 7342 < 0.05
  Ferritin, mg/L 1,472 1,323 1,620 0.29
  Fibrinogen, mg/dL 623 632 614 0.41
  LDH, U/L 482 545 420 0.09
BMI: body mass index; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; CHF: congestive heart 
failure; N: number; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase.
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the two groups. Compared to the patients who survived, the 
peak values of ferritin, LDH, CRP and D-dimer level were sig-
nificantly higher in patients who died (Supplementary Mate-
rial 1, www.jocmr.org). The average hospital LOS was longer 
in the patients who lived compared to the patients who died 
at the end of hospitalization (18 vs. 12, P < 0.05). Majority of 
the patients who survived were discharged to either inpatient 
rehabilitation (42%) or skilled nursing facilities (30%).
Discussion
Our experience with critically ill COVID-19 patients showed 
an overall mortality lower than previous reports [5]. More 
importantly, we noticed a significant improvement in mortal-
ity rates over time, and this difference in mortality remained 
significant even after adjusting for demographics, underlying 
comorbidities, risk of mortality index, medications and other 
interventions employed during the ICU stay.
Odds of mortality were significantly higher in older pa-
tients and those with higher ESR levels on admission. Higher 
peak values of ferritin, LDH, CRP, D-dimer level during the 
hospital stay, and admission risk of mortality categorized as 
extreme were more likely to die. Moreover, patients who re-
ceived HCQ, were on invasive mechanical ventilation, or re-
ceived epoprostenol sodium during their hospital stay were 
more likely to die.
COVID-19 has been challenging in many aspects and its 
mortality has been significantly higher compared to other pa-
tients with viral pneumonia who get admitted to the ICUs [6]. 
This may be either due to a more deadly disease process or a 
sudden influx of a higher number of patients in the ICUs that 
were not well equipped to handle the influx. However, mortal-
ity from COVID-19 has been consistent across the globe with 
a trend towards a reduction in mortality with time. A meta-
analysis of 24 studies comprising ICU patients revealed an 
overall mortality rate of 41% between the months of March 
to May 2020. It reduced from 50% in March 2020 to 40% at 
the end of May 2020 [7]. These results are consistent with our 
results demonstrating a reduction in mortality over time. A ret-
rospective cohort study from Wuhan, China, early in the dis-
ease course reported ICU mortality up to 90% in the patients 
who received mechanical ventilation during the hospital stay 
[8]. Our results were similar in that the overall mortality rate 
was 79% in the ICU patients who were intubated compared to 
patients who were not.
The most notable finding from our study is that mortality 
significantly improved from the beginning of March to Au-
gust. Even after adjusting for geographical location and meta-
regression by month, the publications revealed that mortality 
had significantly decreased all around the globe over time, 
starting from China later followed by reports from Europe and 
North America [7]. Similarly, Intensive Care National Audit 
& Research Centre (ICNARC) reports reveal a peak at 52% 
in April, and a trend towards a reduction in mortality in the 
following months [9]. Despite variation in admission criteria 
to the ICU and difference in relative proportions of patients 
receiving non-invasive versus invasive mechanical ventilation, 
with non-invasive mechanical ventilation being more preva-
lent in Asia than Europe and America, ICU mortality did not 
differ significantly across the continents. Similarly, there was 
a difference in the proportion of use of anti-viral drugs, immu-
nomodulatory treatments and corticosteroids such as HCQ use 
more prevalent in Asia than Europe and North America, but 
the reduction in mortality over time has been uniform all over 
the world [9, 10].
The reasons for this reduction in mortality over time are 
likely multifactorial. Increased awareness with growing medi-
cal literature might have led to a reduction in mortality over 
time. Earlier studies were based on small patient populations 
and may have overestimated mortality. Another factor cited by 
public health officials contributing to a reduction in mortality 
is the shift in demographics towards the younger population 
making up the bulk of new infections [11]. An observational 
study conducted by researchers at the University of Detroit, 
Michigan compared the viral load of patients using the RT-
PCR who were hospitalized between April and June 2020. 
They noticed a significant reduction in the “high viral load 
category” from 25.5% in the first week of study to virtually 
zero percent in the sixth week [12]. This downward trend in 
initial viral load may reflect a reduction in the severity of the 
Table 2.  Crude and Adjusted Mortality Trend by Month
Month Admissions (n) Mortality (%) P value AOR (95% CI) P value
March 142 46 < 0.05 16.81 (3.59 - 78.78) < 0.05
April 530 46 10.25 (2.58 - 40.79) < 0.05
May 290 38 5.59 (1.48 - 21.14) < 0.05
June 105 25 3.46 (.793 - 15.13) 0.09
July 88 23 2.73 (0.64 - 11.58) 0.18
August 49 14 Reference group
Total 1,204 39 < 0.05
Factors that were adjusted for mortality trend by month included patients’ age, gender, ethnicity, comorbidities (diabetes mellitus, hypertension, dys-
lipidemia, heart failure, smoking, chronic obstructive pulmonary disease, asthma, atrial fibrillation, chronic kidney disease, and stroke), medications 
(hydroxychloroquine, tocilizumab, remdesivir, steroids), admission laboratory values (CRP, ESR, D-dimer, ferritin, fibrinogen, lactate dehydrogenase) 
and admission risk of mortality score. AOR: adjusted odds ratio; CI: confidence interval; CRP: C-reactive protein; ESR: erythrocyte sedimentation 
rate.
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pandemic suggesting that viral load may serve as a marker to 
assess the progress of the pandemic. Lastly, an increase in the 
experience that health care providers obtained throughout the 
pandemic, the advancement in research through various clini-
cal trials that have standardized various therapies despite not 
finding a cure and protocol improvements among institutions 
over time are some of the unmeasurable factors that may have 
contributed to this reduction in mortality over time.
Several limitations should be considered while interpret-
ing the results of our study. A causal relationship could not be 
established due to the retrospective and non-randomized na-
ture of the study. This study includes patients from 14 differ-
Table 3.  ICU Interventions, Peak Laboratory Values and Outcomes in COVID-19 Patients
Interventions All (n) Alive n (%) Died n (%) P value Odds ratio
N 1,204 734 (61) 470 (39) < 0.05
Mechanical ventilation 713 340 (46) 373 (79) < 0.05 0.22 (0.12 - 0.29)
  Duration 7 ± 13 7 ± 9 0.44
BiPAP 399 212 (29) 187 (40) < 0.05 0.62 (0.48 - 0.79)
  Duration 1 ± 3 1 ± 3 0.12
ECMO 27 16 (2%) 11 (2) 0.85 0.93 (0.43 - 2.01)
  Duration 1 ± 0.1 1 ± 0.15 0.85
Nitric oxide 2 1 (0.1) 1 (0.2) 0.75 0.64 (0.40 - 10.25)
HFNC 573 370 (50) 203 (43) < 0.05 1.33 (1.05 - 1.68)
Flolan 97 26 (3.5) 71 (15) < 0.05 0.20 (0.13 - 0.32)
Medications
  HCQ 476 265 (56) 211 (44) < 0.05 1.44 (1.13 - 1.82)
    Duration 2 ± 3 2 ± 3 0.17
  TCZ 272 162 (60) 110 (40) 0.64 0.93 (0.70 - 1.22)
    Duration 0.3 ± 0.6 0.3 ± 0.6 0.29
  Remdesivir 162 105 (65) 57 (35) 0.32 1.21 (0.86 - 1.71)
    Duration 1 ± 2 1 ± 2 0.29
  Steroids 602 357 (59) 245 (41) 0.26 0.87 (0.69 - 1.09)
    Duration 4 ± 6 4 ± 6 0.84
Laboratory values
  D-dimer peak 5,912 4,483 7,342 < 0.05
  Ferritin peak 3,942 1,953 5,931 < 0.05
  LDH peak 782 567 998 < 0.05
  CRP peak 22 20 24 < 0.05
  ESR peak 65 68 62 0.46
Outcomes
  Comfort care 136 11 (2) 125 (26) < 0.05 0.04 (0.02 - 0.07)
  Hospital LOS 18 ± 16 12 ± 10 < 0.05
  ICU LOS 9 ± 12 8 ± 9 0.08
Discharge location 716
  Inpatient rehabilitation 295 (42)
  SNF 212 (30)
  Home/NH 137 (19)
  Hospice 56 (8)
  AMA 8 (1)
ICU: intensive care unit; BiPAP: bilevel positive airway pressure; ECMO: extracorporeal membrane oxygenation; HFNC: high-flow nasal cannula; 
HCQ: hydroxychloroquine; TCZ: tocilizumab; LOS: length of stay; LDH: lactate dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimen-
tation rate; SNF: skilled nursing facility; NH: nursing home; AMA: against medical advice.
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ent hospitals of Jefferson Enterprise and there were unmeas-
urable variations in approach to patient care among all the 
hospitals. The impact of variations in ICU admission criteria, 
differences in the expertise of ICU staff, threshold for start-
ing invasive mechanical ventilation and the initiation of sev-
eral adjunctive therapies at the treating physician’s discretion 
could not be determined. We chose laboratory values on day 1 
of admission to the ICU, day 10 into ICU stay and peak values 
throughout ICU stay because the average duration of any ther-
apy for COVID-19 was less than 10 days. Given the variable 
frequency of laboratory specimen collection, we cannot as-
certain if these values represented pre and post-treatment val-
ues accurately in all cases. Lastly, our study was not designed 
to evaluate the contribution of underlying comorbidities to 
COVID-19 mortality, nor the potential adverse effects of ad-
junctive interventions. Many questions remain unanswered; 
however, by adjusting the adult patients with the confirmed 
disease, we believe our population is representative of the 
real-world cohort. Our current COVID-19 treatment practices 
mimic other hospital systems, and we believe these results to 
be generalizable.
Conclusions
Our experience with critically ill COVID-19 patients showed 
an overall mortality lower than previous reports. More impor-
tantly, there was a significant improvement in mortality rates 
over time. However, contributing factors largely remain un-
known. We believe that improving our understanding of COV-
ID-19 pathophysiology, standardizing management protocols 
based on continually evolving data and a decreasing viral load 
over time are important factors that may have improved out-
comes in COVID-19 patients admitted to the ICU. Research is 
needed to further elucidate the factors contributing to mortality 
in critically ill COVID-19 patients.
Supplementary Material
Suppl 1. Comparison of labs on admission, on day 10 of hos-
pitalization, and peak levels during hospitalization.
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